Hairy Cell Leukemia News and Research

RSS
Hairy cell leukemia is a cancer of the blood and bone marrow. This rare type of leukemia gets worse slowly or does not get worse at all. The disease is called hairy cell leukemia because the leukemia cells look "hairy" when viewed under a microscope. Normally, the bone marrow makes blood stem cells (immature cells) that develop into mature blood cells over time. A blood stem cell may become a myeloid stem cell or a lymphoid stem cell.
Celltrion and iProgen Biotech announce partnership for development of novel ADCs

Celltrion and iProgen Biotech announce partnership for development of novel ADCs

FDA approves new treatment for people with hairy cell leukemia

FDA approves new treatment for people with hairy cell leukemia

Novel treatment for hairy cell leukemia approved by FDA

Novel treatment for hairy cell leukemia approved by FDA

Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen seeks FDA approval for leukemia drug blinatumomab

FDA approves ibrutinib for treatment of mantle cell lymphoma

FDA approves ibrutinib for treatment of mantle cell lymphoma

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

TrovaGene acquires license to mutations of SF3B1 splicing factor in CLL

TrovaGene acquires license to mutations of SF3B1 splicing factor in CLL

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

New VA regulation helps to get recognition, treatment for three disorders in Agent Orange exposure

New VA regulation helps to get recognition, treatment for three disorders in Agent Orange exposure

VA prepares to expand Agent Orange related claims for Vietnam veterans

VA prepares to expand Agent Orange related claims for Vietnam veterans

Final regulation to aid Veterans exposed to herbicides published in 'Federal Register'

Final regulation to aid Veterans exposed to herbicides published in 'Federal Register'

VA to develop fully automated, online system for handling disability compensation claims

VA to develop fully automated, online system for handling disability compensation claims

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Research findings open door to development of new therapies for lymphomas, leukemias

Research findings open door to development of new therapies for lymphomas, leukemias

Agent Orange exposure: VA adds three new illnesses to list of health problems

Agent Orange exposure: VA adds three new illnesses to list of health problems